Formulation development and in vitro evaluation of nanosuspensions loaded with Atorvastatin calcium

Main Article Content

Arunkumar N
Deecaraman M
Rani C
Mohanraj K P
Venkateskumar K

Abstract

The aim of this study was to prepare and characterize nanosuspensions of a poorly soluble drug (Atorvastatin calcium) in order to enhance its solubility and dissolution characteristics. Nanosuspensions were prepared by high pressure
homogenization technique.They were characterized by thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), solubility, and in vitro drug release studies. The absence of atorvastatin peaks in PXRD profiles of nanosuspensions suggests the transformation of crystalline drug into an amorphous form.TGA examination suggested that the drug was converted into anhydrous form from the original trihydrate form. DSC curves also compliment the result obtained by TGA and PXRD. The effect of particle size was found to be significant on the saturation solubility of the drug.The in vitro drug release studies showed a significant increase in the dissolution rate of nanosuspensions as compared with pure drug. This study has shown that initial crystalline state is reduced following particle size reduction and that the
dissolution characteristics of atorvastatin nanosuspensions were significantly increased in regards to the pure drug.The method
being simple and easily scaled up, this approach should have a general applicability to many poorly water-soluble drug entities.

Downloads

Download data is not yet available.

Article Details

How to Cite
N, A., M, D., C, R., K P, M., & K, V. (2014). Formulation development and in vitro evaluation of nanosuspensions loaded with Atorvastatin calcium. Asian Journal of Pharmaceutics (AJP), 4(1). https://doi.org/10.22377/ajp.v4i1.119
Section
Articles

References

The Bio pharmaceutics Classification System (BCS) Guidance, Office of

Pharmaceutical Science. Available from: http://www.fda.gov/cder/OPS/

BCS_guidance.htm. [last accessed on 2008 Jan 12].

Clewlow PJ. Survival of the smartest: Scrip’s target world drug delivery

news. Informa Healthcare, UK 2004;35:316-23.

Seedher N, Kaur J. Solubilization of nimesulide: Use of co-solvents.

Indian J Pharm Sci 2003;65:58-61.

Mersiko-Liversidge E, MGurk SL, Liversidge GG. Insulin nanoparticles:

A novel formulation approach for poorly water soluble Zn-Insulin.

Pharm Res 2004;21:1545-53.

Benjamin C, Lu Y, Zang D, Sheng W. Solubility enhancement in

supercritical fluids. Pure Appl Chem 1990;62:2277-85.

Paradkar A, Ambike A, Jadhav B, Mahadik K. Characterization of

curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm

;271:281-6.

Anzai K, Mizoguchi J, Yanagi T, Hirayama F, Arima H, Uekama K.

Improvement of dissolution properties of a new Helicobacter pylori

eradicating agent (TG44) by inclusion complexation with beta-

cyclodextrin. Chem Pharm Bull 2007;55:1466-70.

Sucker H. Hydrosole, eine Alternative für die parenterale Anwendung

von schwer wasserlöslichen Wirkstoffen. In: Muller RH, Hildebrand

GE, editors. Pharmazeutische Technologie; Modern Arzneiformen. 2nd

ed. Stuttgart: WVG; 1998.

Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin

Pharmacokinet 2003;42:1141-60.

Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New

insights into the pharmacodynamic and pharmacokinetic propserties

of statins. Pharmacol Ther 1999;84:413-28.

Hecq J, Deleers M, Fanara D, Vrandex H, Amighi K. Preparation and

characterization of nanocrystals for solubility and dissolution rate

enhancement of nifedipine. Int J Pharm 2005;299:167-77.

Gohel MC, Patel LD. Processing of Nimesulide-PEG 400-PEG-PVP solid

dispersions: Preparation, characterization and in vitro dissolution. Drug

Dev Ind Pharm 2003;29:299-310.

Sunil KB, Michael AR, Soumyajit M, Rao Y. Formulation and evaluation

of rapidly disintegrating Fenoverine tablets: Effect of superdisintegrant.

Drug Dev Ind Pharm 2007;33:1225-32.

Mehdi A, Maryam K, Monireh A. The study of drug permeation through

natural membrane. Int J Pharm 2006;327:6-11.

Giovanna C, Francesca M, Marzia C, Sandra F, Paola M. Development

and evaluation of an in vitro method for prediction of human drug

absorption 1: Assessment of artificial membrane composition. Eur J

Pharm Sci 2006;27:346-53.

Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubertb RH, et al. Preparation,

characterization and in vivo evaluation of amorphous atorvastatin

calcium nanoparticles using supercritical antisolvent (SAS) process.

Eur J Pharm Biopharm 2008;69:454-65.

Kocbek P, Baumgartner S, Kristi J. Preparation and evaluation of

nanosuspensions for enhancing dissolution of poorly soluble drugs.

Int J Pharm 2006;312:179-86.

Yuichi T, Atsutoshi I, Hiiroko S, Toshio O, Keiji Y. Characterization

and quantitation of Clarithromycin polymorphs by powder X-Ray

diffractometry and solid state NMR spectroscopy. Chem Pharm Bull

;50:1128-30.

Jacobs C, Muller RH. Production and characterization of budenoside

nanosuspensions for pulmonary administration. Pharm Res

;19:189-94.

Kim JS, Kim MS, Park HJ, Jin SJ, Sibeum L, Hwang SJ. Physiochemical

properties and oral bioavailability of amorphous atrovastatin hemi-

calcium using spray-drying and SAS process. Int J Pharm 2008;

:211-9.